DOCSLIB.ORG

4Th Good Clinical Practice (GCP) Course September 28-30, 2008 – Szeged, Hungary Program 1 28 September 2008 (Sunday) 13:00-15

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
4Th Good Clinical Practice (GCP) Course September 28-30, 2008 – Szeged, Hungary Program 1 28 September 2008 (Sunday) 13:00-15 4th Good Clinical Practice (GCP) Course September 28-30, 2008 – Szeged, Hungary Program 28 September 2008 (Sunday) 13:00-15:30 Registration Hotel Novotel Szeged**** - Address: Maros utca 1. H-6721 Szeged, Hungary 15:30-16:00 Opening ceremony Introduction of the Presidium. Short allocutions. Narrator: Márta Szűcs Prof. Dr. Gábor Szabó, Rector, University of Szeged, Hungary Prof. Dr. György Benedek, Dean, Faculty of Medicine, University of Szeged, Hungary Dr. László Botka, Mayor of Szeged, Hungary Dr. Helena von Hertzen, Medical Officer, Department of Reproductive Health and Research (RHR), World Health Organization, Geneva, Switzerland Dr. Gábor Szepesi, President of the Hungarian Clinical Trial Management Society, Hungary Prof. Dr. Attila Pál, President of the Albert Szent-Györgyi Clinical Center, University of Szeged, Hungary Prof. Dr. György Bártfai, Chairman of the Organizing and Scientific Committee, Department of Obstetrics and Gynaecology, University of Szeged, Hungary Handing over the Diploma of Honorary Membership of the Hungarian Society of Obstetrics and Gynaecology Prof. Dr. Attila Pál, President of the Hungarian Society of Obstetrics and Gynaecology Scientific Program I. Chairs: Helena von Hertzen MD, Professor Attila Pál 16:00-16:30 Homo sapiens; an undefiniable entity – 30’ Professor Egon Diczfalusy (Karolinska Institutet, Stockholm, Sweden) 16:30-17:00 Reproductive attitudes: warning natality trends in the DKMT euroregion – 30’ Professor Aleksandra Novakov Mikic (Department of Obstetrics and Gynaecology, Clinical Center Novi Sad, Serbia) 17:00-17:15 Coffee break Scientific Program II. Chairs: Professor Tihomir Vejnovic, Gábor Szepesi MD 17:15-17:45 Responsibilities of regulatory authorities in Clinical Trials – 30’ Krisztina Szabóné Nemesy PharmDr (National Institute of Pharmacy, Budapest, Hungary) 17:45-18:15 The impact of the randomized trials of gynaecological surgery on Good Clinical Practice – 30’ Professor Serban-Dan Costa (Department of Obstetrics and Gynaecology, Otto-von-Guericke University, Magdeburg, Germany) 19:00-20:30 Concert of the Chamber Orchestra Weiner at the New Synagogue (bus transfer from the Hotel Novotel Szeged at 18:30) 20:45- Welcome reception at the Hotel Novotel Szeged 1 4th Good Clinical Practice (GCP) Course September 28-30, 2008 – Szeged, Hungary Program 29 September 2008 (Monday) Scientific Program III. Chairs: Professor Ferenc Hajnal, Paja Momcilov MD 8:00-8:20 Practical Issues of Central Ethics Committies – 20’ Professor János Julesz (Endocrine Unit, 1st Department of Internal Medicine, University of Szeged, Szeged, Hungary) 8:20-8:40 Human Drug Development: Phases and Methods – 20’ Gábor Renczes MD (GR Goodwill Research Ltd., Budapest, Hungary) 8:40-9:00 Declaration of Helsinki and Ethics Committee - 20’ Dorottya Mogyorósi MD (Medical Research Council, Ministry of Health, Budapest, Hungary) 9:00-9:20 Understanding thrombophilia in women and consequences for clinical practice– 20’ Professor Thomas Rabe (Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany) 9:20-9:40 Discussion 9:40-10:00 Coffee break Scientific Program IV. Chairs: Ottó Skorán MD, Pavle Vukojevic MD 10:00-10:30 Clinical trial regulations – the Romanian experience - 30’ Cristina Dragomirescu MD (IFE Romania Srl., Timisoara, Romania) 10:30-10:50 Operational issues of Clinical Trials (part I): pre-trial activities, site evaluation, site initiation procedures - 20’ Judit Tarnai MD (Pharm-Olam Hungary Medical Research Ltd., Budapest, Hungary) 10:50-11:10 Operational issues of Clinical Trials (part II) interim monitoring, close-down procedures - 20’ Zsuzsanna Scheily MD (Baxter Nutrition, Medication Delivery, Maurepas, France) 11:10-11:30 Clinical Trial Site: Requirements - 20’ Zsuzsanna Lengyel MD (Ominis Ltd., Budapest, Hungary) 11:30-12:00 The Investigator: Role and Responsibilities - 30’ Edgar Fenzl MD (FGK Clinical Research GmbH, Munich, Germany) 12:00-12:20 The Sponsor: Role and Responsibilities - 20’ Csilla Pozsgay MD (MSD Hungary Ltd., Budapest, Hungary) 12:20-12:30 Discussion 12:30-14:00 Lunch 2 4th Good Clinical Practice (GCP) Course September 28-30, 2008 – Szeged, Hungary Program Scientific Program V. Chairs: Professor Tibor Wittmann 14:00-14:30 GCP - clinical research procedure - the Russian experience - 30’ Alexey Butylin MD (Crocusmedical, Moscow, Russia) 14:30-14:50 Human drug development: Biotechnology, Biosimilars / The Sponsor’s aspects - 20’ Ildikó Aradi MD (Richter Gedeon Plc., Budapest, Hungary) 14:50-15:20 Informed Consent Process: WHO Guidelines - 30’ Helena von Hertzen MD (WHO, Geneva, Switzerland) 15:20-15:40 Informed Consent Process: Special Issues, Pediatric and Vulnerable Patients - 20’ Professor Lajos Kósa (National Clinic for Allergy, Immunology and Pulmonology, Svábhegy, Budapest, Hungary) 15:40-16:00 Discussion 16:00-16:30 Coffee break Scientific Program VI. Chairs: Judit Tarnai MD, Professor Sándor Kerpel-Fronius 16:30-18:10 Vaccination and gen therapy - Round Table Discussion Advanced therapy and biological medicinal products, vaccination Introductory remarks Professor Sándor Kerpel-Fronius (Institute of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary) Participants: Special conditions in clinical development of targeted biological therapies Zsolt Szabó MD (Amgen Ltd. Budapest, Hungary) Specific aspects of vaccine clinical trials József Kovács MD (GlaxoSmithKline Ltd., Budapest, Hungary) Combined artificial chromosome-stem cell therapy Professor Gyula Hadlaczky (Institute of Genetics, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary) Vaccines, answer to pandemic diseases Csaba Kovács MD (Novartis Vaccines, Budapest, Hungary) 18:10-18:30 Discussion 20:00- Tisza-Party, Dinner at the Kiskőrössy Fishermann’s Inn (bus transfer from the Hotel Novotel Szeged at 19:45) 3 4th Good Clinical Practice (GCP) Course September 28-30, 2008 – Szeged, Hungary Program 30 September 2008 (Tuesday) Scientific program VII. Chairs: Cristina Dragomirescu MD, Csilla Pozsgay MD 8:00-8:30 Adverse Events: Definitions and Reporting - 30’ Helena von Hertzen MD (WHO, Geneva, Switzerland) 8:30-8:50 ICH guidelines – 20’ László Veres MD, Quintiles Ltd., Budapest, Hungary) 8:50-9:10 How to prepare for a successful audit? – 20’ Kálmán Juszku MD (AstraZeneca Ltd., Törökbálint, Hungary) 9:10-9:30 Discussion 9:30-10:00 Coffee break Scientific program VIII. Chair: Professor János Borvendég 10:00-11:20 Patient Reported Outcome - Round Table Discussion Patient Reported Outcomes Measures Opening remarks Professor János Borvendég, Coordinator (Hungarian Medical Research Council, Ministry of Health, Budapest, Hungary) Participants: Health related quality of life: assessment and significance in the clinical practice István Mucsi MD (1st Department of Internal Medicine and Institute of Behavioral Sciences, Semmelweis University, Budapest, Hungary) Use of QoL measurement in clinical trials and its application for priority setting Zoltán Kaló MD (Health Economics Research Centre, Eötvös Lóránd University, Budapest, Hungary) The assessment of quality of life in diabetes Professor Gyula Soltész (Department of Paediatrics, University of Pécs, Pécs, Hungary) 11:20-11:40 Discussion Scientific program IX. Chair: Professor György Bártfai 11:40-12:10 Valedictory lecture: The Ethics of Medicine and of Society - GCP – 30’ Professor Miguel Oliveira da Silva (Institute of Preventive Medicine, University of Lisboa, Portugal) 12:10-12:50 Written test 12:50-13:00 Closing remarks 13:00- Lunch 4 .
Load more

Recommended publications
  • Curriculum Vitae: Prof. Dr. Med. Thomas Rabe
    Curriculum vitae: Prof. Dr. med. Thomas Rabe PERSONAL Date of birth February 18, 1951 Nationality German EDUCATION School 1957-1961 Primary School in Gaggenau 1961-1969 Goethe-Gymnasium in Gaggenau (Abitur) University 1969-1975 Study of medicine at the University of Heidelberg 1973-1975 Thesis of doctorate at the Department of Biochemistry II (Chairman: Prof. Dr. Dr.R. Brossmer): HCG (human chorionic gonadotropin) in vitro assay and pharmcocinetic studies of cyclic AMP in the rat testis. DEGREES 1975 Medical state board exam 1976 German Doctor`s Licence 1976-1983 Residency at the University Women’s Hospital in Heidelberg, specialisation on gynecological endocrinology and reproductive medicine 1985 Assistant professor in Obstetrics and Gynecology 1991 Associate professor in Obstetrics and Gynecology EMPLOYMENT/ POSITION Since 1985 Consultant at the Division of Gynecological Endocrinology and at the University Women’s Hospital, Heidelberg 2001 Call for a professorship of Gynecological Endocrinology and Re- productive Medicine at the Charité University Hospital in Berlin, Germany, which I refused. ACTVITIES Scientific More than 200 scientific publications and more than 20 textbooks as author or coauthor (partially translated into 10 languages): e.g., Rabe & Runnebaum: Kontrazeption, Springer 1983; Runnebaum, Rabe, Kiesel: Future aspects in Contraception: Male and Female, MTP, Lancaster, 1985; Runnebaum & Rabe: Gynäkologische End- okrinologie, Springer 1987 and 1994 (German and English edi- tion); Rabe: Gynäkologie und Geburtshilfe, Lehrbuch, 1989; Rabe: Memorix (Pocket Guide): Gynecology and Obstetrics, 1991; Rabe, Runnebaum (eds): Fertility Control, Springer, 1998; Rabe, Die- drich, Runnebaum (eds): Manual on Assisted Reproduction 1997, 2nd edition 2000; Rabe & Strowitzi (eds): Lifestyle and Anti- Aging Medizin (1999, 2000, 2001) Page 1/2 Curriculum vitae: Prof.
    [Show full text]
  • Annual Report 20 Annual Report 2020
    ANNUAL REPORT 20 ANNUAL REPORT 2020 OUR PURPOSE THROUGH SPORT, WE HAVE THE POWER TO CHANGE LIVES OUR MISSION TO BE THE BEST SPORTS BRAND IN THE WORLD OUR ATTITUDE IMPOSSIBLE IS NOTHING 2 ANNUAL REPORT 2020 ADIDAS ANNUAL REPORT 2020 TO OUR SHAREHOLDERS Letter from the CEO 008 Business Performance by Segment 161 Executive Board 013 Outlook 168 Supervisory Board 017 Risk and Opportunity Report 172 Supervisory Board Report 021 Illustration of Risks 181 Illustration of Opportunities 188 Declaration on Corporate Governance 031 Management Assessment of Performance, Compensation Report 040 Risks and Opportunities, and Outlook 190 Our Share 063 CONSOLIDATED FINANCIAL GROUP MANAGEMENT REPORT STATEMENTS OUR COMPANY Consolidated Statement of Financial Position 194 Strategy 069 Consolidated Income Statement 196 Global Brands 074 Consolidated Statement of Global Sales 079 Comprehensive Income 197 Global Operations 084 Consolidated Statement of Changes in Equity 198 Our People 089 Consolidated Statement of Cash Flows 199 Culture 094 Notes 201 Sustainability 101 Notes to the Consolidated Statement of Financial Position 221 Our Approach 101 Notes to the Consolidated Income Statement 274 Our Progress 104 Additional Information 281 Environmental Impacts 104 Social Impacts 112 Shareholdings 292 Working Conditions in Our Supply Chain 114 Responsibility Statement 295 Non-Financial Statement 124 Reproduction of the Independent Auditor’s Report 296 GROUP MANAGEMENT REPORT Limited Assurance Report of the FINANCIAL REVIEW Independent Auditor Regarding the Internal
    [Show full text]
  • Curriculum Vitae: Prof. Dr. Med. Thomas Rabe
    Curriculum vitae: Prof. Dr. med. Thomas Rabe PERSONAL Date of birth February 18, 1951 Nationality German EDUCATION School 1957-1961 Primary School in Gaggenau 1961-1969 Goethe-Gymnasium in Gaggenau (Abitur) University 1969-1975 Study of medicine at the University of Heidelberg 1973-1975 Thesis of doctorate at the Department of Biochemistry II (Chairman: Prof. Dr. Dr.R. Brossmer): HCG (human chorionic gonadotropin) in vitro assay and pharmcocinetic studies of cyclic AMP in the rat testis. DEGREES 1975 Medical state board exam 1976 German Doctor`s Licence 1976-1983 Residency at the University Women’s Hospital in Heidelberg, specialisation on gynecological endocrinology and reproductive medicine 1985 Assistant professor in Obstetrics and Gynecology 1991 Associate professor in Obstetrics and Gynecology EMPLOYMENT/ POSITION Since 1985 Consultant at the Division of Gynecological Endocrinology and at the University Women’s Hospital, Heidelberg 2001 Call for a professorship of Gynecological Endocrinology and Re- productive Medicine at the Charité University Hospital in Berlin, Germany, which I refused. ACTVITIES Scientific More than 200 scientific publications and more than 20 textbooks as author or coauthor (partially translated into 10 languages): e.g., Rabe & Runnebaum: Kontrazeption, Springer 1983; Runnebaum, Rabe, Kiesel: Future aspects in Contraception: Male and Female, MTP, Lancaster, 1985; Runnebaum & Rabe: Gynäkologische End- okrinologie, Springer 1987 and 1994 (German and English edi- tion); Rabe: Gynäkologie und Geburtshilfe, Lehrbuch, 1989; Rabe: Memorix (Pocket Guide): Gynecology and Obstetrics, 1991; Rabe, Runnebaum (eds): Fertility Control, Springer, 1998; Rabe, Die- drich, Runnebaum (eds): Manual on Assisted Reproduction 1997, 2nd edition 2000; Rabe & Strowitzi (eds): Lifestyle and Anti- Aging Medizin (1999, 2000, 2001) Page 1/2 Curriculum vitae: Prof.
    [Show full text]
  • Reproductive Health B5
    Gynecological obstetric Section Association for Reproductive Health Empathy, Science, Hope Serbian Medical Society Egon and Ann Diczfalusy Foundation for Supporting Research in Reproductive Health THE 7th DICZFALUSY AWARD LECTURE SYMPOSIUM ON REPRODUCTIVE HEALTH Co Organizers: Association for Reproductive Health, University of Belgrade, School of Medicine & Gynecological obstetric Section of Serbian Medical Society 27 – 28th September 2013 Hotel Hyatt Regency Belgrade, Serbia THE 7th DICZFALUSY AWARD LECTURE SYMPOSIUM ON REPRODUCTIVE HEALTH GENERAL SPONSOR GOLDEN SPONSOR SILVER SPONSOR SPONSORS THE 7th DICZFALUSY AWARD LECTURE SYMPOSIUM ON REPRODUCTIVE HEALTH Gynecological obstetric Section Association for Reproductive Health Empathy, Science, Hope Serbian Medical Society PROGRAM Egon and Ann Diczfalusy Foundation for Supporting Research in Reproductive Health THE 7th DICZFALUSY AWARD LECTURE SYMPOSIUM ON REPRODUCTIVE HEALTH Co Organizers: Association for Reproductive Health, University of Belgrade, School of Medicine & Gynecological obstetric Section of Serbian Medical Society 27 – 28th September 2013 Hotel Hyatt Regency Belgrade, Serbia THE 7th DICZFALUSY AWARD LECTURE SYMPOSIUM ON REPRODUCTIVE HEALTH ORGANIZING COMMITTEE President: Doc. dr Ana Mitrović Jovanović Members: Prof. dr Bártfai György Prof. dr Tihomir Vejnović Prof. dr Nebojša Lalić Prof. dr Snežana Rakić Dr Vesna Kršić Ass. dr Vesna Mandić Mr sci.dr Petar Radlović SCIENTIFIC COMMITTEE Prof. dr Guiseppe Benagiano Dr Christi Furau Prof. dr. Bártfai György Doc. dr Ana Mitrović Jovanović Prof. dr David Archer Prof. dr Nebojša Lalić Prof. dr Henry Gabelnic Prof. dr Dušan Stanojević Prof. dr Thomas Rabe Prof. dr Gordana Radonjić Lazović Prof. dr Britt-Marie Landgren Akademik Prof. dr Nebojša Radunović Prof. dr Petru Chitulea Dr sci. med. Katarina Sedlecki Prof. Attila Pal Prof.
    [Show full text]
  • Die Welt Von Bertelsmann the World of 2 INSIDE Die Digitale Welt Von Bertelsmann the Digital World of Bertelsmann
    Juni/June 2014 INSIDE Das internationale Magazin für Bertelsmann-Mitarbeiterinnen und -Mitarbeiter | The international magazine for Bertelsmann employees Die Welt von Bertelsmann The World of 2 INSIDE Die digitale Welt von Bertelsmann The digital world of Bertelsmann Mehr als 2.000 Social-Media-Kanäle auf einen Blick: die Bertelsmann Social Cloud More than 2,000 social media channels at a glance: the Bertelsmann Social Cloud http://socialcloud.bertelsmann.com/ Editorial INSIDE 3 Eine Reise durch die Bertelsmann-Welt A Journey Through the Karin Schlautmann Leiterin Unternehmenskommunikation, World of Bertelsmann Bertelsmann SE & Co. KGaA Head of Corporate Communications, Bertelsmann SE & Co. KGaA Dass Bertelsmann internationaler werden soll, gehört zu den erklärten strategischen Zielsetzungen unseres Un- ternehmens. Wie international Bertelsmann heute schon ist und wie groß die Vielfalt bei uns ist, zeigen mir immer wieder die Gespräche mit Kollegen in aller Welt. Ob wir uns in London, Paris oder Madrid, aber auch in Peking, Becoming a more international company is one of São Paulo oder jüngst in Neu-Delhi mit den Verantwort- Bertelsmann’s declared strategic objectives. Time and lichen vor Ort treffen – es entsteht überall dasselbe again, in talking with colleagues all over the world, I re- Bild: Bertelsmann ist in seinen Kernmärkten stark und alize how international and diverse Bertelsmann already wird in seinen Wachstumsmärkten immer stärker. Doch is. Whether we meet with local managers in London, diese Meetings zeigen, wie wichtig es ist, dass wir uns Paris, Madrid, Beijing, São Paulo or most recently in bei Bertelsmann in den einzelnen Ländern und Märkten New Delhi, the same picture emerges everywhere: über die Grenzen von Bereichen hinweg austauschen.
    [Show full text]
  • Financial Statements and Management Report AG 2008/09
    Annual financial statements and management report of IKB Deutsche Industriebank AG 20082009 4 Executive Bodies and Committees 4 Supervisory Board and Committees 6 Advisory Board 9 Board of Managing Directors 10 Management Report of IKB Deutsche Industriebank AG 11 1. Business and general conditions 14 2. Significant events in the reporting period 26 3. Net assets, financial position and results of operations 33 4. Risk report 72 5. Events after 31 March 2009 (Supplementary report) 75 6. Outlook 79 7. Remuneration report 88 8. Other financial information 93 Annual Financial Statements of IKB Deutsche Industriebank AG 94 Balance sheet 96 Income statement 98 Notes 98 Notes to the annual financial statements 98 Accounting policies 104 Other special matters 107 Notes on the balance sheet 114 Development of capital 120 Notes on the income statement 122 Other disclosures 135 Auditor’s Report 137 Responsibility statement in line with section 264 (2) sentence 3 HGB, section 289 (1) sentence 5 HGB 4 Supervisory Board and Committees Supervisory Board Bruno Scherrer Head of European Investments, Senior Managing Director, (Chairman) Lone Star Management Europe Ltd., London Dr Karsten von Köller Chairman Lone Star Germany GmbH, Frankfurt am Main (Deputy Chairman) Stefan A. Baustert President and CEO SINGULUS TECHNOLOGIES AG, Bad Homburg Wolfgang Bouché* Düsseldorf Olivier Brahin Head of European Real Estate Investments, Lone Star Management Europe Ltd., London Dr Lutz-Christian Funke Director of Business Strategy/Head of Staff Division Board of Directors of KfW Bankengruppe, Frankfurt am Main Ulrich Grillo Chairman of the Board of Managing Directors of Grillo-Werke AG, Mülheim an der Ruhr Arndt G.
    [Show full text]
  • Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized Shrsp Rats
    J Am Soc Nephrol 15: 348–358, 2004 Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats MARIE-LUISE GROSS,* MARCIN ADAMCZAK,†‡ THOMAS RABE,§ NEVIN ALI HARBI,† JAN KRTIL,† ANDREAS KOCH,* PETER HAMAR,࿣ KERSTIN AMANN,¶ and EBERHARD RITZ† Departments of *Pathology and †Internal Medicine, University of Heidelberg, Heidelberg, Germany; ‡Department of Nephrology, Endocrinology, and Metabolic Diseases, Medical University of Silesia, Katowice, Poland; §Department of Gynecological Endocrinology and Reproductive Medicine, University Women’s Hospital, Heidelberg, Germany; ࿣Institute of Pathophysiology, Semmelweis University, Budapest, Hungary; and ¶Department of Pathology, University of Erlangen, Erlangen, Germany. Abstract. Renal diseases tend to be less severe among pre- estradiol-treated animals (estradiol-treated UNX/OVX ani- menopausal female patients, compared with male patients. mals, 0.69 Ϯ 0.16; estriol-treated UNX/OVX animals, 0.21 Ϯ Experimental data on the effects of estrogens on renal damage 0.12; P Ͻ 0.05), compared with vehicle-treated animals (1.46 are controversial, and potential underlying mechanisms have Ϯ 0.09); the tubulointerstitial damage index exhibited a similar not been fully clarified. Three-month-old, female, uninephrec- pattern. The mean glomerular volume was significantly less in tomized (UNX), sham-operated or ovariectomized (OVX) estrogen-treated animals. UNX/OVX animals demonstrated SHRsp rats were left untreated or received either 17␤-estradiol significantly greater expression of TGF-␤ and endothelin-1 in 3-benzoate (25 ␮g/d) or estriol (0.02 mg/d) daily. After 3 mo, immunohistochemical, in situ hybridization, and reverse tran- indices of renal damage (glomerulosclerosis index and tubulo- scription-PCR assays. This increase was abrogated by estriol interstitial damage index) and glomerular geometric parame- but not estradiol.
    [Show full text]
  • Diczfalusy 2016 Programfuzet Belivek3.Indd
    10th Diczfalusy Meeting Egon and Ann Diczfalusy Foundation for Supporting Research in Reproductive Health In collaboration with the Medical Universities of Novi Sad (Ser bia) and Szeged (Hungary) University of Szeged; The Reproductive Health-working Group of the Szeged branch of the Hungarian Academy of Science; „Vasile Goldiș” Western University of Arad (Romania); The Serbian Academy of Sciences and Arts - branch in Novi Sad; The Serbian Medical Association - Section of Gynaecology and Obstetrics, Association of Gynaecologist and Obstetricians of Serbia, Montenegro and Republic of Serbia 10th Annual Meeting of the Egon and Ann Diczfalusy Foundation • Programme 30 November – 2 December 2016 10th Diczfalusy Meeting Dear Colleagues, The aim of the “Egon & Ann Diczfalusy Foundation” is to support research in reproductive health and to provide updated knowledge to Obstetricians-Gynaecologists in Central-Eastern Europe. To foster its aims, every year the Foundation organises an Annual Meeting with a Diczfalusy Award Lecture Symposium (DAL) on Reproductive Health. This year the Diczfalusy Foundation will organise its 10th Annual Meeting, the DAL 10 between 30 November and 2 December 2016 in Budapest, Hungary. This meeting will have a special significance as we will celebrate the 10th year anniversary of the Foundation established by Professor Egon Diczfalusy. On behalf of the Scientific Committee and the Presidium of the Foundation, It is our pleasure and privilege to invite you to participate in this event. We look forward to the pleasure of welcoming you in Budapest! Yours sincerely, Prof. Dr. György Bártfai president of the Foundation 2 10th Diczfalusy Meeting In Memoriam Prof. Dr. Egon Diczfalusy The Hungarian and international academic community suffered a great loss when Prof.
    [Show full text]
  • Life As a Program Buyer Has Changed, but Attention Hasn't
    THE BUSINESS JOURNAL OF FILM, BROADCASTING, BROADBAND, PRODUCTION, DISTRIBUTION SEPTEMBER/OCTOBER 2012 VOL. 32 NO. 5 $9.75 In This Issue: Sports on TV MIPCOM Preview NATPE’s “Big Five-O” Europe’s Big Spenders ® www.videoage.org Life As a Program Buyer Has The 2012-13 Season is “Disaster” Changed, But Attention Hasn’t in Dramas, “Losers” in Comedies BY LUCY COHEN BLATTER he fall U.S. TV season is in Nevertheless, U.S. studios at MIPCOM t isn’t easy being a program buyer these days. Advertising dollars are down and full swing and international will be betting on their key shows, viewer alternatives are up. Local production is down in many parts of the world program distributors and regardless of the reception they get and cost of imported programs is up. Competition is increasing and the budget broadcasters alike are waiting at home. For example, CBS Studios to face it decreasing in many instances. with bated breath to see which International will be highlighting four Plus, the buying business shows will be successful and models are ever-changing which will likely go (Continued on Page 50) with exclusivity often a the distance — both in the Ithing of the past, and shared TU.S. and internationally. windows a new reality. And the Content Piracy in LATAM: challenges are not over yet, with As pointed out in a new technological TV formats to VideoAge report last May, A Costly Issue All Around contend with, such as 3D. in 2011 the U.S. supplied BY DOM SERAFINI If all these weren’t enough, 72 percent of primetime consider the TV trade shows imported drama series to ast May a group of major U.S.
    [Show full text]